US · ARQT
Arcutis Biotherapeutics, Inc.
- Sector
- Healthcare · Biotechnology
- Headquarters
- Westlake Village, CA 91361
- Website
- arcutis.com
Price · as of 2025-12-31
$23.35
Market cap 3.3B
Valuation summary
Four models, one snapshot. Upside is target ÷ current − 1.
| Valuation method | Value, $ | Upside, % |
|---|---|---|
| Artificial Intelligence(AI) | $50.04 | +114.3% |
| Intrinsic Value(DCF) | $25,121.07 | +107,484.88% |
| Graham-Dodd Method(GD) | $0.86 | -96.34% |
| Graham Formula(GF) | — | — |
Valuation history
Annual price (USD per share) overlaid with each model's fair value. Y-axis is log scale.
| Year | Price | AI | DCF | Graham-Dodd | Graham Formula |
|---|---|---|---|---|---|
| 2011 | |||||
| 2012 | |||||
| 2013 | |||||
| 2014 | |||||
| 2015 | |||||
| 2016 | |||||
| 2017 | |||||
| 2018 | |||||
| 2019 | $28.25 | ||||
| 2020 | $32.55 | ||||
| 2021 | $16.85 | ||||
| 2022 | $12.09 | ||||
| 2023 | $11.15 | $197.96 | $0.00 | $0.00 | $0.00 |
| 2024 | $14.72 | $51.94 | $0.00 | $0.00 | $0.00 |
| 2025 | $24.76 | $50.04 | $140,084.88 | $0.85 | $0.00 |
AI valuation
Our deep-learning model estimates Arcutis Biotherapeutics, Inc.'s (ARQT) per-share fair value from quarterly fundamentals, sector trend, and historical valuation patterns.
- AI fair value
- $50.04
- Current price
- $23.35
- AI upside
- +114.3%
Methodology and confidence bands appear in the dedicated valuation theory section. The AI score is an estimate, not a recommendation.
Intrinsic value (DCF)
Open DCF calculatorThree textbook valuation models, recomputed daily from the latest financial statements. The DCF uses our Chepakovich model. Graham-Dodd and Graham Formula are conservative reference points.
DCF
$25,121.07
+107,484.88% upside
Graham-Dodd
$0.86
-96.34% upside
Graham Formula
—
— upside
Peer comparison
Same-industry comparables, ranked by market cap.
| Basic Info | Model Valuation | Core Valuation | Profitability | Leverage & Liquidity | Growth | Cash Flow | Dividends | Enterprise Value | Risk | ||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Ticker | Company Name | Price | Market Cap | AI Upside | DCF Upside | GD Upside | GF Upside | P/E | P/B | P/S | EV/EBITDA | PEG | P/TBV | Gross Margin | Operating Margin | Net Margin | ROE | ROIC | ROA | Debt/Equity | Interest Coverage | Current Ratio | Quick Ratio | Net Debt/EBITDA | EPS Growth | Sales Growth | FCF Growth | FCF Yield | Op Cash Flow Ratio | Cash ROIC | Dividend Yield | Dividend Payout | Shareholder Yield | EV/EBIT | EV/FCF | EV/Sales | Altman Z-Score |
| ARQT | Arcutis Biotherapeutics, … | $23.35 | 3.3B | +114% | +107,485% | -96% | — | -195.17 | 16.63 | 8.38 | 1183.71 | — | 18.04 | 90.24% | -3.25% | -4.29% | -9.30% | -163.75% | -4.13% | 0.03 | -1.01 | 3.17 | 2.83 | -14.77 | -8879.00% | 9134.00% | -9438.00% | -0.20% | -0.04 | -84.52% | 0.00% | 0.00% | 2.41% | -240.09 | -465.16 | 7.81 | 5.64 |
| CELC | Celcuity Inc. | $111.71 | 5.17B | — | — | — | — | -3.76 | 3.63 | — | -2.79 | -72.15 | 3.63 | 0.00% | — | — | -87.54% | 909.82% | -51.23% | 0.85 | -11.02 | 7.71 | 7.46 | -0.74 | 520.00% | — | 5529.00% | -19.94% | -2.63 | 672.45% | 0.00% | 0.00% | 0.00% | -2.49 | -3.38 | — | -0.09 |
| CGON | CG Oncology, Inc. Common … | $58.80 | 4.74B | +6% | +153% | — | — | -27.73 | 5.93 | 1105.21 | -23.38 | -58.37 | 6.02 | -15.02% | -4722.13% | -3985.02% | -21.67% | -4199.76% | -20.82% | 0.01 | — | 24.63 | 24.09 | 0.16 | 4752.00% | 25470.00% | 6781.00% | -2.97% | -4.29 | -2916.46% | 0.00% | 0.00% | 0.00% | -19.55 | -28.15 | 923.25 | 68.35 |
| CNTA | Centessa Pharmaceuticals … | $26.86 | 3.61B | +34% | — | — | — | -7.88 | 4.63 | — | -6.73 | -25.25 | 4.63 | 0.00% | — | — | -73.93% | -398.61% | -50.32% | 0.29 | -19.93 | 9.25 | 9.09 | 1.20 | 3121.00% | -10000.00% | -1148.00% | -7.65% | -2.45 | -281.71% | 0.00% | 0.00% | 11.98% | -7.43 | -10.51 | — | 3.81 |
| FOLD | Amicus Therapeutics, Inc. | $14.37 | 4.51B | +149% | -39% | — | — | -163.34 | 16.15 | 6.98 | 85.82 | — | 70.82 | 87.32% | 5.44% | -4.27% | -11.58% | 3.24% | -3.13% | 1.76 | 0.75 | 2.84 | 1.72 | 5.00 | -5117.00% | 2005.00% | -17972.00% | 0.67% | 0.14 | 7.01% | 0.00% | 0.00% | 0.00% | 133.89 | 154.71 | 7.28 | 1.20 |
| IRON | Disc Medicine, Inc. | $66.62 | 2.51B | — | — | — | — | -11.07 | 3.17 | — | -7.50 | -21.38 | 3.17 | 0.00% | — | — | -35.86% | 717.87% | -32.55% | 0.00 | -65.43 | 21.94 | 21.59 | 0.43 | 5177.00% | — | 9202.00% | -7.72% | -4.92 | 551.51% | 0.00% | 0.00% | 0.00% | -6.61 | -8.60 | — | 20.31 |
| LEGN | Legend Biotech Corporatio… | $19.00 | 1.75B | +139% | +396,718% | -91% | — | -20.39 | 3.10 | 5.14 | -21.66 | — | 3.72 | 62.60% | -48.35% | -28.22% | -13.80% | -112.36% | -8.99% | 0.34 | -14.03 | 4.62 | 4.49 | -0.56 | -6701.00% | 11997.00% | -6199.00% | -4.91% | -0.52 | -58.59% | 0.00% | 0.00% | 0.00% | -8.08 | -15.50 | 3.91 | 2.18 |
| TARS | Tarsus Pharmaceuticals, I… | $75.52 | 3.21B | +33% | +191,318% | -100% | — | -48.71 | 9.42 | 7.17 | -54.31 | — | 9.63 | 93.20% | -15.72% | -14.72% | -23.39% | -558.70% | -14.14% | 0.27 | -7.94 | 3.85 | 3.72 | 1.68 | -4821.00% | 14671.00% | -7363.00% | -0.69% | -0.09 | -175.63% | 0.00% | 0.00% | 2.09% | -41.03 | -130.51 | 6.45 | 9.02 |
| TVTX | Travere Therapeutics, Inc… | $29.79 | 2.67B | +90% | +51,751% | — | — | -103.12 | 22.94 | 5.37 | 118.84 | — | 2744.19 | 85.51% | -12.80% | -10.24% | -29.38% | -59.63% | -4.26% | 2.86 | -5.85 | 2.74 | 2.52 | 10.61 | -8627.00% | 11045.00% | -11116.00% | 1.43% | 0.24 | 35.86% | 0.00% | 0.00% | 4.07% | -42.03 | 69.88 | 5.38 | 0.84 |
| XENE | Xenon Pharmaceuticals Inc… | $43.23 | 3.34B | — | -58% | — | — | -9.75 | 5.80 | 449.63 | -8.27 | -21.74 | 5.80 | 66.09% | -4974.27% | -4612.13% | -51.76% | -419.58% | -48.34% | 0.01 | — | 13.13 | 13.17 | 0.56 | 4485.00% | — | 5175.00% | -8.30% | -6.68 | -314.81% | 0.00% | 0.00% | 1.71% | -7.59 | -10.11 | 377.51 | 35.64 |
| ZLAB | Zai Lab Limited | $19.22 | 2.13B | +50% | -49% | — | — | -11.49 | 2.82 | 4.38 | -9.81 | — | 3.16 | 58.60% | -49.86% | -38.15% | -22.56% | -97.09% | -14.89% | 0.31 | -44.05 | 2.45 | 1.91 | 2.88 | -3846.00% | 1533.00% | -4251.00% | -7.88% | -0.36 | -68.36% | 0.00% | 0.00% | 7.89% | -6.77 | -9.77 | 3.37 | -0.13 |
About Arcutis Biotherapeutics, Inc.
Arcutis Biotherapeutics, Inc., a biopharmaceutical company, focuses on developing and commercializing treatments for dermatological diseases. Its lead product candidate is ARQ-151, a topical roflumilast cream that has completed Phase III clinical trials for the treatment of plaque psoriasis and atopic dermatitis. The company is also developing ARQ-154, a topical foam formulation of roflumilast for the treatment of seborrheic dermatitis and scalp psoriasis; ARQ-252, a selective topical janus kinase type 1 inhibitor for hand eczema and vitiligo; and ARQ-255, a topical formulation of ARQ-252 designed to reach deeper into the skin in order to treat alopecia areata. The company was formerly known as Arcutis, Inc. and changed its name to Arcutis Biotherapeutics, Inc. in October 2019. Arcutis Biotherapeutics, Inc. was incorporated in 2016 and is headquartered in Westlake Village, California.
- CEO
- Todd Franklin Watanabe
- Employees
- 342
- Beta
- 1.68
Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Upside computed as ($25,121.07 ÷ $23.35) − 1 = +107,484.88% (DCF, example).